

D Mr. Iñigo de la Lastra
Head of Secondary Markets
CNMV
Edison, 4
28006 Madrid

St Joan Despi, Barcelona (Spain), February 16, 2015

RELEVANT FACT

Dear Sir,

In accordance with Law 24/1988, 28th July, relative to the regulation of the stock market and related provisions, LABORATORIO REIG JOFRE, SA, ("Reig Jofre" or "the Company"), formerly NATRACEUTICAL, SA ("Natraceutical") submits hereafter a press release regarding the completion of the integration process between Natraceutical and Reig Jofre.

Yours faithfully,

Adolf Rousaud
Secretary of the Board of Directors
Laboratorio Reig Jofre, SA

Completion of the merger between Natraceutical and Reig Jofre

The new shares of Reig Jofre start trading today

Sant Joan Despi, Barcelona (Spain) February 16, 2015. The new shares of Laboratorio Reig Jofre SA issued to cover the assets exchange of the merger between Natraceutical SA and Laboratorio Reig Jofre SA, start trading today, thus concluding the integration process between the two companies.

In particular, after verification by the Spanish Stock Exchange Commission (CNMV) of the compliance with all requirements and informative prospectus, 935,570,462 shares have been admitted to trading, delivered in full to Reig Jofre Investments SL, asset-holding company of the Reig family and sole shareholder of Reig Jofre before the merger with Natraceutical. The new titles are ordinary shares, all of the same class, series and par value as those outstanding before the merger between the two companies. The informative prospectus is available on the public registers of the CNMV and on the investors section of Reig Jofre's website¹.

After this issue, the equity of the new company is made of 1,264,284,408 shares, which places the market capitalization of Reig Jofre after the last market closing at 297 million euros.

Since last Friday, February 13, the shares of the former Natraceutical, which changed its name to Laboratorio Reig Jofre SA, trade under the ticker RJF (formerly NTC).

Headquartered in Sant Joan Despi, Barcelona (Spain) Reig Jofre is now the fifth quoted Spanish pharmaceutical company by turnover. With sales of 150 million euros (aggregated data from 2013), the new Reig Jofre is completely vertically integrated and strengthened its market position by diversifying its product portfolio in the segments of pharma (69% of the combined sales in 2013), OTC (16%) and food supplements (15%), as well as its international presence, whose sales outside Spain represent 64% of the joint turnover, distributed between France (17%), Germany (10%), UK (9%), Sweden (6%) and about fifty other countries on five continents (21%).

At the beginning of 2015 the new company appointed its board of directors, headed by Isabel Reig as non-executive chair of the company, representing Reig Jofre Investments SL, and Ignasi Biosca as CEO. Also, the board has five independent directors of recognized professional experience in the pharmaceutical industry, scientific research, finance and capital markets, internationalization marketing and advertising.

About Reig Jofre

The new Reig Jofre is a pharmaceutical company whose business is divided into two major areas: one main for the development, manufacture and marketing of own products (approximately 73% of sales) and one of specialized manufacturing for thirds (27% of sales). At its core activity, the company specializes in the development of prescription and non-prescription pharmaceutical products, generics based on specialized technologies, medical devices, nutritional supplements and cosmetics.



The company directs its R&D to develop new indications and/or dosage forms of known active principles, generics with special focus on beta lactam and lyophilized injectable antibiotics, topical dermatological products, OTCs and nutritional supplements as well as the development of new innovative molecules in partnership with start-ups and research centers.

Reig Jofre trades on the Spanish stock exchange under the ticker RJF. Total outstanding shares: 1,264,284,408

For more information

Media

Ricard Franco

Inforpress

Tel. +34 93 419 06 30

rfranco@inforpress.es

Investors and analysts

Gloria Folch

Head of Investor Relations

Reig Jofre

Tel. +34 93 584 81 85

gloria.folch@reigjofre.com

ⁱ Until further notice, www.natraceuticalgroup.com